Premium
Prospects for new lung cancer treatments that target EMT signaling
Author(s) -
Otsuki Yuji,
Saya Hideyuki,
Arima Yoshimi
Publication year - 2018
Publication title -
developmental dynamics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.634
H-Index - 141
eISSN - 1097-0177
pISSN - 1058-8388
DOI - 10.1002/dvdy.24596
Subject(s) - lung cancer , epithelial–mesenchymal transition , cancer , anaplastic lymphoma kinase , cancer research , epidermal growth factor receptor , metastasis , malignancy , biology , radiation therapy , targeted therapy , signal transduction , treatment of lung cancer , oncology , medicine , biochemistry , malignant pleural effusion
Lung cancer is the most common cancer worldwide. Treatment options for lung cancer include surgery, radiation therapy, chemotherapy, molecularly targeted therapy including epidermal growth factor receptor or anaplastic lymphoma kinase inhibitors, and immunotherapy. These treatments can be administered alone or in combination. Despite therapeutic advances, however, lung cancer remains the leading cause of cancer death. Recent studies have indicated that epithelial‐mesenchymal transition (EMT) is associated with malignancy in various types of cancer, and activation of EMT signaling in cancer cells is widely considered to contribute to metastasis, recurrence, or therapeutic resistance. In this review, we provide an overview of the role of EMT in the progression of lung cancer. We also discuss the prospects for new therapeutic strategies that target EMT signaling in lung cancer. Developmental Dynamics 247:462–472, 2018 . © 2017 Wiley Periodicals, Inc.